Articles tagged “regulation”
4 articles
PCAC July 2026 Results: What the FDA Advisory Committee Decided on 7 Peptides
The FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 to evaluate 7 peptide compounds for 503A inclusion. Here's what they decided and what it means for patients, clinics, and the compounding industry.
503A vs 503B: What's the Difference Between Compounding Pharmacies?
The terms 503A and 503B come up constantly in peptide therapy discussions, but most patients have no idea what they mean. Here's a clear breakdown of the two types of compounding pharmacies, how they're regulated, and why it matters for your peptide prescription.
The History of Peptide Regulation: From the 2023 Ban to the 2026 Reversal
How 19 peptides went from legally compoundable to banned to partially restored in three years — a timeline of the most turbulent period in peptide regulatory history.
The 2026 FDA Peptide Reclassification: What Changed and What It Means
In February 2026, 14 peptides were reclassified from Category 2 to Category 1. Here's what that means for patients, clinics, and the peptide market.